Drug profile · INN
anisotropine methylbromide
ANISOTROPINE METHYLBROMIDE
anisotropine methylbromide (ANISOTROPINE METHYLBROMIDE) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — anisotropine methylbromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
anisotropine methylbromide (ANISOTROPINE METHYLBROMIDE) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is anisotropine methylbromide?
anisotropine methylbromide (ANISOTROPINE METHYLBROMIDE) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for anisotropine methylbromide?
ANISOTROPINE METHYLBROMIDE is a marketed brand name for anisotropine methylbromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anisotropine methylbromide?
anisotropine methylbromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.